Abstract
Although complete remission (CR) is achieved in 50 to 70% of older fit patients with acute myeloid leukemia (AML), consolidation therapy in this age group remains challenging. In this retrospective study, we aimed to compare outcome in elderly patients treated with different post-remission modalities, including allogenic and autologous hematopoietic stem cell transplantation (HSCT), intensive chemotherapy, and standard-dose chemotherapy (repeated 1 + 5 regimen). We collected data of 441 patients ≥ 60 years in first CR from a single institution. Median age was 67 years. Sixty-one (14%) patients received allo-HSCT, 51 (12%) auto-HSCT, 70 (16%) intensive chemotherapy with intermediate- or high-dose cytarabine (I/HDAC), and 190 (43%) 1 + 5 regimen. Median follow-up was 6.5 years. In multivariate analysis, allo-HSCT, cytogenetics, and PS had a significant impact on OS and LFS. In spite of a more favorable-risk profile, the patients who received I/HDAC had no significantly better LFS as compared with patients treated with 1 + 5 (median LFS 8.8 months vs 10.6 months, p = 0.96). In transplanted patients, median LFS was 13.3 months for auto-HSCT and 25.8 months for allo-HSCT. Pre-transplant chemotherapy with I/HDAC had no effect on the outcome. Toxicity was significantly increased for both transplanted and non-transplanted patients treated with I/HDAC, with more units of blood and platelet transfusion and more time spent in hospitalization, but no higher non-relapse mortality. This study shows that post-remission chemotherapy intensification is not associated with significantly better outcome as compared with standard-dose chemotherapy in elderly patients for whom, overall results remain disappointing.
References
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447
Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM et al (1992) Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79(8):1924–1930
Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331(14):896–903
Estey E, Döhner H (2006) Acute myeloid leukaemia. Lancet Lond Engl 368(9550):1894–1907
Estey EH (2000) How I treat older patients with AML. Blood 96(5):1670–1673
Fröhling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Döhner K et al (2006) Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 108(10):3280–3288
Etienne A, Esterni B, Charbonnier A, Mozziconacci M-J, Arnoulet C, Coso D et al (2007) Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 109(7):1376–1383
Vey N (2013) Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress? Interdiscip Top Gerontol 38:73–84
Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS et al (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94(3):1086–1099
Pigneux A, Béné MC, Guardiola P, Recher C, Hamel J-F, Sauvezie M et al (2016) Addition of androgens improves survival in elderly patients with acute myeloid leukemia: a GOELAMS study. J Clin Oncol 35(4):387–393
Pigneux A, Béné MC, Salmi LR, Dumas PY, Delaunay J, Bonmati C, Guièze R1, Luquet I, Cornillet-Lefebvre P, Delabesse E, Ianotto JC, Ojeda-Uribe M, Hunault M, Banos A, Fornecker LM, Bernard M, Jourdan E, Vey N, Zerazhi H, Hishri Y, Mineur A, Asselineau J, Delepine R, Cahn JY, Ifrah N, Récher C, French Innovative Leukemia Organization (2018) Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. J Clin Oncol. https://doi.org/10.1200/JCO.2018.78.7366
Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N et al (2007) Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109(12):5129–5135
Itzykson R, Gardin C, Pautas C, Thomas X, Turlure P, Raffoux E et al (2011) Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica 96(6):837–844
Huls G, Chitu DA, Havelange V, Jongen-Lavrencic M, van de Loosdrecht AA, Biemond BJ et al (2019) Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood 133(13):1457–1464
Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie J-N et al (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379(9825):1508–1516
Vey N, Dumas P-Y, Recher C, Gastaud L, Lioure B, Bulabois C-E et al (2017) Randomized phase 2 trial of lirilumab (anti-KIR monoclonal antibody, mAb) as maintenance treatment in elderly patients (pts) with acute myeloid leukemia (AML): results of the Effikir trial. Blood 130(Suppl 1):889–889
Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP et al (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98(3):548–553
Pigneux A, Perreau V, Jourdan E, Vey N, Dastugue N, Huguet F et al (2007) Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. Haematologica 92(10):1327–1334
Byrd JC, Ruppert AS, Mrózek K, Carroll AJ, Edwards CG, Arthur DC et al (2004) Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 22(6):1087–1094
Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J et al (1999) Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17(12):3767–3775
Prébet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn J-Y et al (2009) Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol 27(28):4747–4753
Ghimire KB, Shah BK (2014) Second primary malignancies in adult acute myeloid leukemia--a US population-based study. Anticancer Res 34(7):3855–3859
Tallman MS, Rowlings PA, Milone G, Zhang MJ, Perez WS, Weisdorf D et al (2000) Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 96(4):1254–1258
Warlick ED, Paulson K, Brazauskas R, Zhong X, Miller AM, Camitta BM et al (2014) Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant 20(2):202–208
Rashidi A, Linden MA, DeFor TE, Warlick E, Bejanyan N, Yohe S et al (2017) History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol 92(10):1032–1036
Cerrano M, Itzykson R (2019) New treatment options for acute myeloid leukemia in 2019. Curr Oncol Rep 21(2):16
Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG (2018) al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med 378(13):1189–1199
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bouchacourt, B., Hospital, M.A., Zemmour, C. et al. Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome. Ann Hematol 99, 773–780 (2020). https://doi.org/10.1007/s00277-020-03922-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-020-03922-w